219 related articles for article (PubMed ID: 24930599)
1. Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.
Kimani D; Jagne YJ; Cox M; Kimani E; Bliss CM; Gitau E; Ogwang C; Afolabi MO; Bowyer G; Collins KA; Edwards N; Hodgson SH; Duncan CJ; Spencer AJ; Knight MG; Drammeh A; Anagnostou NA; Berrie E; Moyle S; Gilbert SC; Soipei P; Okebe J; Colloca S; Cortese R; Viebig NK; Roberts R; Lawrie AM; Nicosia A; Imoukhuede EB; Bejon P; Chilengi R; Bojang K; Flanagan KL; Hill AV; Urban BC; Ewer KJ
Mol Ther; 2014 Nov; 22(11):1992-2003. PubMed ID: 24930599
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
Ogwang C; Afolabi M; Kimani D; Jagne YJ; Sheehy SH; Bliss CM; Duncan CJ; Collins KA; Garcia Knight MA; Kimani E; Anagnostou NA; Berrie E; Moyle S; Gilbert SC; Spencer AJ; Soipei P; Mueller J; Okebe J; Colloca S; Cortese R; Viebig NK; Roberts R; Gantlett K; Lawrie AM; Nicosia A; Imoukhuede EB; Bejon P; Urban BC; Flanagan KL; Ewer KJ; Chilengi R; Hill AV; Bojang K
PLoS One; 2013; 8(3):e57726. PubMed ID: 23526949
[TBL] [Abstract][Full Text] [Related]
3. Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.
Mensah VA; Gueye A; Ndiaye M; Edwards NJ; Wright D; Anagnostou NA; Syll M; Ndaw A; Abiola A; Bliss C; Gomis JF; Petersen I; Ogwang C; Dieye T; Viebig NK; Lawrie AM; Roberts R; Nicosia A; Faye B; Gaye O; Leroy O; Imoukhuede EB; Ewer KJ; Bejon P; Hill AV; Cisse B;
PLoS One; 2016; 11(12):e0167951. PubMed ID: 27978537
[TBL] [Abstract][Full Text] [Related]
4. A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults.
Sklar MJ; Maiolatesi S; Patterson N; Sedegah M; Limbach K; Teneza-Mora N; Chuang I; Hollis-Perry KM; Banania JG; Guzman I; Ganeshan H; Reyes S; Hollingdale MR; Wong M; Lindstrom A; Reyes A; Alcorta Y; Garver L; Bankard K; Belmonte A; Belmonte M; Huang J; Gowda K; Inoue S; Velasco R; Bergmann-Leitner E; Hutter J; Lee T; Adams N; Chaudhury S; Hunt D; Tamminga C; Berrie E; Bellamy D; Bittaye M; Ewer K; Diggs C; Soisson LA; Lawrie A; Hill A; Richie TL; Villasante E; Epstein JE; Duplessis CA
PLoS One; 2021; 16(9):e0256980. PubMed ID: 34495988
[TBL] [Abstract][Full Text] [Related]
5. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
Sheehy SH; Duncan CJ; Elias SC; Biswas S; Collins KA; O'Hara GA; Halstead FD; Ewer KJ; Mahungu T; Spencer AJ; Miura K; Poulton ID; Dicks MD; Edwards NJ; Berrie E; Moyle S; Colloca S; Cortese R; Gantlett K; Long CA; Lawrie AM; Gilbert SC; Doherty T; Nicosia A; Hill AV; Draper SJ
PLoS One; 2012; 7(2):e31208. PubMed ID: 22363582
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™.
Venkatraman N; Anagnostou N; Bliss C; Bowyer G; Wright D; Lövgren-Bengtsson K; Roberts R; Poulton I; Lawrie A; Ewer K; V S Hill A
Vaccine; 2017 Oct; 35(45):6208-6217. PubMed ID: 28941620
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.
Moorthy VS; Imoukhuede EB; Keating S; Pinder M; Webster D; Skinner MA; Gilbert SC; Walraven G; Hill AV
J Infect Dis; 2004 Jun; 189(12):2213-9. PubMed ID: 15181568
[TBL] [Abstract][Full Text] [Related]
8. Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants.
Afolabi MO; Tiono AB; Adetifa UJ; Yaro JB; Drammeh A; Nébié I; Bliss C; Hodgson SH; Anagnostou NA; Sanou GS; Jagne YJ; Ouedraogo O; Tamara C; Ouedraogo N; Ouedraogo M; Njie-Jobe J; Diarra A; Duncan CJ; Cortese R; Nicosia A; Roberts R; Viebig NK; Leroy O; Lawrie AM; Flanagan KL; Kampman B; Bejon P; Imoukhuede EB; Ewer KJ; Hill AV; Bojang K; Sirima SB
Mol Ther; 2016 Aug; 24(8):1470-7. PubMed ID: 27109630
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.
Hodgson SH; Ewer KJ; Bliss CM; Edwards NJ; Rampling T; Anagnostou NA; de Barra E; Havelock T; Bowyer G; Poulton ID; de Cassan S; Longley R; Illingworth JJ; Douglas AD; Mange PB; Collins KA; Roberts R; Gerry S; Berrie E; Moyle S; Colloca S; Cortese R; Sinden RE; Gilbert SC; Bejon P; Lawrie AM; Nicosia A; Faust SN; Hill AV
J Infect Dis; 2015 Apr; 211(7):1076-86. PubMed ID: 25336730
[TBL] [Abstract][Full Text] [Related]
10. Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP.
Bliss CM; Bowyer G; Anagnostou NA; Havelock T; Snudden CM; Davies H; de Cassan SC; Grobbelaar A; Lawrie AM; Venkatraman N; Poulton ID; Roberts R; Mange PB; Choudhary P; Faust SN; Colloca S; Gilbert SC; Nicosia A; Hill AVS; Ewer KJ
Sci Rep; 2018 Feb; 8(1):3390. PubMed ID: 29467399
[TBL] [Abstract][Full Text] [Related]
11. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.
Dunachie SJ; Walther M; Epstein JE; Keating S; Berthoud T; Andrews L; Andersen RF; Bejon P; Goonetilleke N; Poulton I; Webster DP; Butcher G; Watkins K; Sinden RE; Levine GL; Richie TL; Schneider J; Kaslow D; Gilbert SC; Carucci DJ; Hill AV
Infect Immun; 2006 Oct; 74(10):5933-42. PubMed ID: 16988273
[TBL] [Abstract][Full Text] [Related]
12. First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children.
Tiono AB; Nébié I; Anagnostou N; Coulibaly AS; Bowyer G; Lam E; Bougouma EC; Ouedraogo A; Yaro JBB; Barry A; Roberts R; Rampling T; Bliss C; Hodgson S; Lawrie A; Ouedraogo A; Imoukhuede EB; Ewer KJ; Viebig NK; Diarra A; Leroy O; Bejon P; Hill AVS; Sirima SB
PLoS One; 2018; 13(12):e0208328. PubMed ID: 30540808
[TBL] [Abstract][Full Text] [Related]
13. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation.
Ewer KJ; O'Hara GA; Duncan CJ; Collins KA; Sheehy SH; Reyes-Sandoval A; Goodman AL; Edwards NJ; Elias SC; Halstead FD; Longley RJ; Rowland R; Poulton ID; Draper SJ; Blagborough AM; Berrie E; Moyle S; Williams N; Siani L; Folgori A; Colloca S; Sinden RE; Lawrie AM; Cortese R; Gilbert SC; Nicosia A; Hill AV
Nat Commun; 2013; 4():2836. PubMed ID: 24284865
[TBL] [Abstract][Full Text] [Related]
14. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.
O'Hara GA; Duncan CJ; Ewer KJ; Collins KA; Elias SC; Halstead FD; Goodman AL; Edwards NJ; Reyes-Sandoval A; Bird P; Rowland R; Sheehy SH; Poulton ID; Hutchings C; Todryk S; Andrews L; Folgori A; Berrie E; Moyle S; Nicosia A; Colloca S; Cortese R; Siani L; Lawrie AM; Gilbert SC; Hill AV
J Infect Dis; 2012 Mar; 205(5):772-81. PubMed ID: 22275401
[TBL] [Abstract][Full Text] [Related]
15. Prime-boost vectored malaria vaccines: progress and prospects.
Hill AV; Reyes-Sandoval A; O'Hara G; Ewer K; Lawrie A; Goodman A; Nicosia A; Folgori A; Colloca S; Cortese R; Gilbert SC; Draper SJ
Hum Vaccin; 2010 Jan; 6(1):78-83. PubMed ID: 20061802
[TBL] [Abstract][Full Text] [Related]
16. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults.
Moorthy VS; Imoukhuede EB; Milligan P; Bojang K; Keating S; Kaye P; Pinder M; Gilbert SC; Walraven G; Greenwood BM; Hill AS
PLoS Med; 2004 Nov; 1(2):e33. PubMed ID: 15526058
[TBL] [Abstract][Full Text] [Related]
17. A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.
de Barra E; Hodgson SH; Ewer KJ; Bliss CM; Hennigan K; Collins A; Berrie E; Lawrie AM; Gilbert SC; Nicosia A; McConkey SJ; Hill AV
PLoS One; 2014; 9(12):e115161. PubMed ID: 25522180
[TBL] [Abstract][Full Text] [Related]
18. Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants.
Bliss CM; Drammeh A; Bowyer G; Sanou GS; Jagne YJ; Ouedraogo O; Edwards NJ; Tarama C; Ouedraogo N; Ouedraogo M; Njie-Jobe J; Diarra A; Afolabi MO; Tiono AB; Yaro JB; Adetifa UJ; Hodgson SH; Anagnostou NA; Roberts R; Duncan CJ; Cortese R; Viebig NK; Leroy O; Lawrie AM; Flanagan KL; Kampmann B; Imoukhuede EB; Sirima SB; Bojang K; Hill AV; Nébié I; Ewer KJ
Mol Ther; 2017 Feb; 25(2):547-559. PubMed ID: 28153101
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
Moorthy VS; Pinder M; Reece WH; Watkins K; Atabani S; Hannan C; Bojang K; McAdam KP; Schneider J; Gilbert S; Hill AV
J Infect Dis; 2003 Oct; 188(8):1239-44. PubMed ID: 14551895
[TBL] [Abstract][Full Text] [Related]
20. Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults.
Ogwang C; Kimani D; Edwards NJ; Roberts R; Mwacharo J; Bowyer G; Bliss C; Hodgson SH; Njuguna P; Viebig NK; Nicosia A; Gitau E; Douglas S; Illingworth J; Marsh K; Lawrie A; Imoukhuede EB; Ewer K; Urban BC; Hill AVS; Bejon P;
Sci Transl Med; 2015 May; 7(286):286re5. PubMed ID: 25947165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
